CN103880907A - Hydrocortisone-17-butyrate semihydrate - Google Patents
Hydrocortisone-17-butyrate semihydrate Download PDFInfo
- Publication number
- CN103880907A CN103880907A CN201410086992.4A CN201410086992A CN103880907A CN 103880907 A CN103880907 A CN 103880907A CN 201410086992 A CN201410086992 A CN 201410086992A CN 103880907 A CN103880907 A CN 103880907A
- Authority
- CN
- China
- Prior art keywords
- semihydrate
- hydrocortisone butyrate
- hours
- constant temperature
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a novel compound, namely a hydrocortisone-17-butyrate semihydrate, a preparation method of the novel compound as well as a pharmaceutical composition.
Description
Technical field
The present invention relates to a kind of new compound-hydrocortisone butyrate semihydrate, especially relate to the preparation method of this compound and the preparation of this compound of use.
Background technology
Hydrocortisone butyrate (Hydrocortisone-17-butyrate, CAS:13609-67-1) be the one of steroidal cortin, can suppress the reaction of inflammation and allergic skin, also suppress to add related reaction of rapid regeneration and cause symptom with cell simultaneously, for example erythema, oedema, thickization of skin, coarse the going down of skin surface, and alleviate the problems such as itch, burning sensation and pain.Owing to having introduced 17-butyric ester on hydrocortisone molecule, make the fat-soluble better of hydrocortisone butyrate, thereby in the time of external curing, can reach better curative effect, retain the lighter advantage of side effect of hydrocortisone simultaneously, be a kind of can be for children's external application steroidal cortin.The main emulsion of hydrocortisone butyrate of existing external preparation (trade(brand)name: You Zhuoer, Tianjin Pharmaceutical Group Corp., Ltd produces, 1994 in Discussion on Chinese Listed).
Test and find that the impurity producing in emulsion of hydrocortisone butyrate is mainly 21-hydrocortisone butyrate in storage process through us, the major cause that produces this impurity is that hydrolysis has occurred 17 ester groups in storage process, and similar transesterification reaction occurs and become hydrocortisone-21-butyric ester with 21 hydroxyls.Hydrocortisone-21-butyric ester (HCB-21) that in the experiment of hydrocortisone butyrate preparation stability, main impurity transesterify produces is also disclosed in U.S. Patent application US20040152682A1 specification sheets the second page table 3, in existing preparation technique with formula in owing to there being a large amount of water, the speed that the transesterification reaction of existing hydrocortisone-21-butyric ester occurs, impurity hydrocortisone-21-the butyric ester producing is more, the stability of product is produced to the interference strengthening, simultaneously because the generation of impurity has also produced certain impact to the curative effect of product.
(horse military camp as everyone knows, the type of carboxyester hydrolysis and influence factor, " Xinyang Normal College's journal: natural science edition ", 11 4 phases of volume in 1998,417-421) tertiary alcohol ester hydrocortisone butyrate can be hydrolyzed under acidity or alkaline condition, but because different pH values can produce larger impact to ester hydrolysis rate.
Summary of the invention
For overcoming the problems of the prior art, the invention provides a kind of new compound-hydrocortisone butyrate semihydrate, by use this compound in paste, suppressing dissociating simultaneously of 17-ester, also suppressed the carrying out of transesterification reaction, more surprisingly this compound is made while directly acting on skin preparation, and Transdermal absorption ability is strengthened, and bioavailability is higher.
A kind of hydrocortisone butyrate semihydrate, structure is as follows
。
Above-mentioned hydrocortisone butyrate semihydrate, is characterized in that its X ray result is diffuse type, there is no sharp-pointed absorption peak.
Above-mentioned hydrocortisone butyrate semihydrate, is characterised in that its differential scanning calorimetric analysis result has endotherm(ic)peak at 185-210 ℃ and 95-120 ℃.
Above-mentioned hydrocortisone butyrate semihydrate, be characterised in that its preparation method is that hydrocortisone butyrate is dissolved in the mixing solutions of tetrahydrofuran (THF), ethanol, add the water of mixed liquor volume 7-13%, then under-70 to-60 ℃ of conditions freezing 2 hours, solution freezes as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 4 hours; Be warming up to 0 ℃, constant temperature 4 hours, rises to 20 ℃ naturally, constant temperature 5 hours, 50 ± 5 ℃ dry, within 1 hour, often digest compound weight differential to interval and be less than or equal to 0.5 milligram and get final product.Above-mentioned hydrocortisone butyrate semihydrate preparation method, wherein preferably tetrahydrofuran (THF) accounts for tetrahydrofuran (THF), alcohol mixed solvent ratio is 0.2 ± 0.05; Wherein preferably add and pass into carbonic acid gas after the water of mixed liquor volume 15-25% and carry out saturated.
A kind of pharmaceutical composition, is characterized in that containing as above-mentioned hydrocortisone butyrate semihydrate and the excipient substance of one or more.
Directly act on a pharmaceutical composition for skin, it is characterized in that containing above-mentioned hydrocortisone butyrate semihydrate and one or more excipient substances as activeconstituents.
Directly act on a pharmaceutical composition for skin, it is characterized in that being formed by the above-mentioned hydrocortisone butyrate semihydrate as activeconstituents and the excipient substance of one or more.
Directly act on a pharmaceutical composition for skin, it is characterized in that by the above-mentioned hydrocortisone butyrate semihydrate as activeconstituents, form as the water of solid, consistency modifiers, wetting Agent for Printing Inks, emulsifying agent, pH buffer reagent, sanitas and the surplus of the oil-phase component of pharmaceutical excipient.Wherein preferably containing as the consumption of the hydrocortisone butyrate semihydrate of activeconstituents is 0.05-0.2%, and the consumption of the described solid as oil-phase component is 3%～20%, is selected from one or more in higher alcohols; Described consistency modifiers, consumption is 5%～20%, is selected from one or more in Vaseline, whiteruss; The consumption of described wetting Agent for Printing Inks is 3%～10%, is selected from multicomponent alcoholics compound; Described emulsifier is 1-10%, is selected from polyoxyethylene ether derivant; Described sanitas consumption is 0.05-0.2%, is selected from parabens sanitas; Described pH adjusting agent is phosphoric acid salt buffer reagent or citric acid/sodium citrate buffer reagent.Wherein preferably hydrocortisone butyrate hemihydrate content is 0.1%.Be preferably wherein stearyl alcohol and/or hexadecanol as the solid of oil-phase component.Wherein preferred described consistency modifiers is one or more in Vaseline, whiteruss.Wherein preferably wetting Agent for Printing Inks is glycerine and/or propylene glycol.Wherein preferred described emulsifying agent is peregal A-20.Wherein preferred described sanitas is ethyl p-hydroxybenzoate.
Wherein preferred described cream formulation is made up of the material of following weight percent: hydrocortisone butyrate semihydrate 0.1%, white vaseline 3-10%, stearyl alcohol 3-10%, whiteruss 3-10%, peregal A-20 1%～5%, glycerine 1-5%, propylene glycol 1-5%, ethyl p-hydroxybenzoate 0.1%, citric acid and Trisodium Citrate amount to 1-3%, citric acid (C
6h
8o
7h
2o): Trisodium Citrate (Na
3c
6h
5o
72H
2o)=1:1.2-1:2.0(weight ratio), surplus is water.
The compound method of above-mentioned emulsifiable paste is as follows: (1) oil phase preparation: take in solid, consistency modifiers, the emulsifying agent heating and melting of oil phase substrate and become solution, temperature remains on 70-90 ℃; (2) water preparation: the water that regulates pH value is mixed, heating, the temperature that stirs remains on 70-90 ℃; Hydrocortisone butyrate micro mist is dispersed in the wetting Agent for Printing Inks of solvent, is then added to the water and stirs, temperature remains on 70-90 ℃; (3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 70-90 ℃, stir 10-30min, be cooled to cream.
The citric acid using in technical solution of the present invention is C
6h
8o
7h
2o, Trisodium Citrate Na
3c
6h
5o
72H
2o
Per-cent in technical solution of the present invention is the weight percent that accounts for emulsifiable paste weight.
Described higher alcohols also plays the effect of tensio-active agent in matrix simultaneously.
Accompanying drawing explanation:
The X-ray powder diffraction collection of illustrative plates (copper target) of the hydrocortisone butyrate semihydrate that Fig. 1: embodiment 1 obtains
Means of differential scanning calorimetry (DSC) collection of illustrative plates of the hydrocortisone butyrate semihydrate that Fig. 2: embodiment 1 obtains
The collection of illustrative plates of embodiment 2-6 and Fig. 1,2 basically identical, omit.
In the present invention, powdery diffractometry instrument used is Rigaku D/max-2500 powder diffractometer, Rigaku company product, Cu-Ka radiation.
Means of differential scanning calorimetry (DSC) collection of illustrative plates of Fig. 2 embodies hydrocortisone butyrate semihydrate and has the process (and hydrocortisone butyrate does not have similar process) that loses crystal water, this proves that this water is to exist with the form of crystal water, and be not planar water, the X-ray powder diffraction collection of illustrative plates simultaneously surprisingly generally with hemihydrated solid generally has characteristic peak, but X-ray powder diffraction collection of illustrative plates in Fig. 1 does not have obvious characteristic peak.
May be Just because of this, in the present invention, hydrocortisone butyrate semihydrate just can have the feature of stability and hypertonicity.
In the present invention, the weight of hydrocortisone butyrate semihydrate is the actual weight that contains hydrocortisone butyrate, and in embodiment, 1g hydrocortisone butyrate semihydrate refers to the hydrocortisone butyrate semihydrate that is equivalent to 1g hydrocortisone butyrate.
Embodiment
Below will by embodiment, the invention will be further described, these descriptions are not that content of the present invention is further limited.One skilled in the art will understand that the replacement that is equal to that technical characterictic of the present invention is done, or improve accordingly, within still belonging to protection scope of the present invention.
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (2:8) mixing solutions 25L, add the water of 2.5L, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
embodiment 2
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (1.5:8.5) mixing solutions 30L, add the water of 3.9L, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
embodiment 3
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (2.5:7.5) mixing solutions 20L, add the water of 1.4L, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
embodiment 4
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (2:8) mixing solutions 25L, add the water of 2.5L, pass into carbonic acid gas carry out saturated after, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
embodiment 5
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (1.5:8.5) mixing solutions 30L, add the water of 3.9L, pass into carbonic acid gas carry out saturated after, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
embodiment 6
Hydrocortisone butyrate 1kg is dissolved in to tetrahydrofuran (THF) entirely: in the mixing solutions of ethanol (2.5:7.5) mixing solutions 20L, add the water of 1.4L, pass into carbonic acid gas carry out saturated after, under-70 to-60 ℃ of conditions freezing 3 hours, solution froze as solid.System is vacuumized, and to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 3 hours; Be warming up to 0 ℃, constant temperature 3 hours, rises to room temperature naturally, and constant temperature 5 hours is dried at 50 ± 5 ℃, within 1 hour, often digests compound weight differential be less than or equal to 0.5 milligram to interval, obtains hydrocortisone butyrate semihydrate.
the test of hydrocortisone butyrate semihydrate physico-chemical property
1, hydrocortisone butyrate semihydrate crystal water assay after drying
Commercially available sample issues for having national Shi Yaojian general bureau the hydrocortisone butyrate that Tianjin Tianyao Pharmaceutical Co., Ltd. of production of raw medicine certification enterprise provides, and patented method sample is the hydrocortisone butyrate of preparing according to the method for authorizing in invention CN200910228789.5.
The measuring method of hydrate existence and content: use the karl Fischer method of describing in 23 editions 1801-1802 of American Pharmacopeia or 1840-1843 method <731> or <921> to measure the water content of dry hydrocortisone butyrate semihydrate (without planar water), wherein the method for dry hydrocortisone butyrate semihydrate refers to by filtering, optionally use a kind of anhydrous solvent as hexane washing 1 time, again filter, then at 60 ℃, in 24 hours, there is no further weight loss.
Hydrate existence and content in embodiment 1-6
Can determine that by this experiment commercially available sample, patented method sample do not contain crystal water, and the solid obtaining by embodiment method contains crystal water, be 2.000% according to calculating crystal water ratio in known hydrocortisone butyrate semihydrate, so embodiment 1-6 is hydrocortisone butyrate semihydrate simultaneously.
, hydrocortisone butyrate semihydrate slope of repose measure
Fixing conical bottom method: chassis is the culture dish of diameter 7cm, two glass funnels are overlapping up and down, be fixed on iron stand, lower hopper outlet and chassis distance are between 3.5-6.0cm. get respectively trial-product, slowly add from upper funnel, auxiliary material is deposited on chassis gradually through the buffering of two funnels, form cone, until obtain the highest cone. measure the high H of cone, every kind of each mensuration three times of sample, averages, and is calculated as follows slope of repose: α=arctg (H/R) wherein, α is slope of repose, and R is chassis radius.
| Trial-product title | Slope of repose (degree) |
| |
27.67 |
| Embodiment 2 | 28.01 |
| Embodiment 3 | 28.32 |
| Embodiment 4 | 27.09 |
| Embodiment 5 | 27.45 |
| Embodiment 6 | 27.59 |
| Commercially available sample | 31.42 |
| Patented method sample | 30.86 |
The mobility that can determine commercially available sample, patented method sample by this experiment is poor compared with embodiment 1-6 sample, and in embodiment 1-6, No. 4-6 better.
The aluminum-plastic laminated tube that the emulsifiable paste that all FORMULATION EXAMPLE make all props up with 10g/ is divided and is packaged spare.
fORMULATION EXAMPLE 1
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 1) 1g,
Auxiliary material: white vaseline 100g, stearyl alcohol 30g, whiteruss 30g, peregal A-20 50g, glycerine 50g, propylene glycol 20g, ethyl p-hydroxybenzoate 1g, citric acid (C
6h
8o
7h
2o) 10g,
Trisodium Citrate (Na
3c
6h
5o
72H
2o) 18g water for injection adds to 1000g
By above proportioning accurate weighing, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation: get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 90 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in water for injection, main ingredient is dispersed in glycerine, propylene glycol, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 90 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 80 ℃, stir 30min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.1%, recording lotion pH is 5.5.
fORMULATION EXAMPLE 2
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 2) 1g,
Auxiliary material: white vaseline 30g, stearyl alcohol 100g, whiteruss 100g, peregal A-20 10g, glycerine 10g, propylene glycol 50g, ethyl p-hydroxybenzoate 1g, citric acid (C
6h
8o
7h
2o) 4g,
Trisodium Citrate (Na
3c
6h
5o
72H
2o) 6g water for injection is to 1000g
By above proportioning accurate weighing, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 75 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in water for injection, main ingredient is dispersed in glycerine, propylene glycol, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 90 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 90 ℃, stir 30min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.1%, recording lotion pH is 5.2.
fORMULATION EXAMPLE 3
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 3) 1g,
Auxiliary material: white vaseline 30g, stearyl alcohol 100g, whiteruss 30g, peregal A-20 30g, glycerine 50g, propylene glycol 50g, ethyl p-hydroxybenzoate 1g, citric acid (C
6h
8o
7h
2o) 10g,
Trisodium Citrate (Na
3c
6h
5o
72H
2o) 20g
Water for injection is to 1000g
By above proportioning accurate weighing, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 85 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in the water for injection of recipe quantity, main ingredient is dispersed in glycerine, propylene glycol, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 80 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 80 ℃, stir 30min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.1%, recording lotion pH is 5.2.
fORMULATION EXAMPLE 4
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 4) 1g,
Auxiliary material: white vaseline 100g, stearyl alcohol 60g, whiteruss 100g, peregal A-20 10g, glycerine 10g, propylene glycol 10g, ethyl p-hydroxybenzoate 1g, citric acid (C
6h
8o
7h
2o) 7g,
Trisodium Citrate (Na
3c
6h
5o
72H
2o) 13g water for injection is to 1000g
By above proportioning accurate weighing, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation: get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 75 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in the water for injection of recipe quantity, main ingredient is dispersed in glycerine, propylene glycol, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 90 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 75 ℃, stir 30min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.1%, recording lotion pH is 5.3.
fORMULATION EXAMPLE 5
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 5) 1g,
Auxiliary material: white vaseline 150g, stearyl alcohol 30g, whiteruss 80g, peregal A-20 80g, glycerine 80g, ethyl p-hydroxybenzoate 1g, citric acid (C
6h
8o
7h
2o) 12g,
Trisodium Citrate (Na
3c
6h
5o
72H
2o) 18g water for injection is to 1000g
By above proportioning accurate weighing, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 90 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in the water for injection of recipe quantity, main ingredient is dispersed in glycerine, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 80 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 90 ℃, stir 30min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.2%, recording lotion pH is 5.2.
fORMULATION EXAMPLE 6
Activeconstituents: hydrocortisone butyrate semihydrate (embodiment 6) 1g,
Auxiliary material: white vaseline 30g, hexadecanol 150g, whiteruss 30g, peregal A-20 10g,
Propylene glycol 30g, citric acid (C
6h
8o
7h
2o) 5g, Trisodium Citrate (Na
3c
6h
5o
72H
2o) 10g
Water for injection is to 1000g
By above proportioning accurate weighing,, emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, stearyl alcohol, whiteruss, peregal A-20 is placed in container, is heated to melting, and temperature remains on 75 ℃;
(2) water preparation: citric acid and Trisodium Citrate are dissolved in the water for injection of recipe quantity, main ingredient is dispersed in propylene glycol, add the aqueous solution of citric acid and Trisodium Citrate, ethyl p-hydroxybenzoate, heating, the temperature that stirs remains on 90 ℃;
(3) close phase: the oil phase of step (1) preparation is slowly added in the water of step (2) preparation, stir, maintain the temperature at 70 ℃, stir 15min, be cooled to cream, obtain 1000g emulsifiable paste, content 0.05%, recording lotion pH is 5.3.
stability under stability embodiment 1 high humidity
High humidity test: trial-product 1g solid on average disperses 16cm
2glass plate on, put in constant humidity encloses container, at 30 ± 2 ℃ of temperature respectively at placing 30 days under relative humidity 90% ± 5% condition, sampling in the 30th day, and (HPLC method is measured hydrocortisone butyrate in hydrocortisone butyrate ointment according to Zhong Weigao, (Huai-Hai medicine, the 24th the 5th phase of volume of September in 2006,428-429) disclosed detection method detects hydrocortisone butyrate (HCB) content and related substance hydrocortisone-21-butyric ester (HCB-21).
Detecting instrument: Japanese Shimadzu LC-IOA high performance liquid chromatograph; SPD-l0A UV-detector
Chromatographic condition: chromatographic column, Shimadzu CIS-ODS post (150mm × 4.6mm, 5 μ are m); Moving phase, methyl alcohol: water: ether (62:38:2); Flow velocity 1.0 ml/min; Sample size, 20 μ L; Column temperature, room temperature; Detect wavelength, UV240 nm.Theoretical plate number is calculated and should be not less than 2 000 by hydrocortisone butyrate.The peak of hydrocortisone butyrate and the resolution of adjacent impurity peaks meet the requirements.
The preparation of reference substance solution, precision takes hydrocortisone butyrate reference substance, and ((assay use, Products in China calibrating provides) 12.0mg, with moving phase dissolving, and is settled to 100m1, shakes up.Be that concentration is the solution that every 1ml approximately contains 0.120mg.
The preparation of sample solution: the about 0.03g of sample thief.Accurately weighed, put in 50ml measuring bottle.Add methyl alcohol appropriate, put 80 ℃ water-soluble in, heating make dissolve, let cool to room temperature, add methyl alcohol and be diluted to scale, shake up.Put cooling 2 h in ice bath.After taking out, filter rapidly, discard just filtrate, get subsequent filtrate as sample solution.
Determining of linear relationship: precision takes hydrocortisone butyrate reference substance (content is 98.79%) 12.0 mg, with methanol solution and make every 1ml approximately containing the solution of 0.120 mg.Precision measures 4,8,10,12,16,20 ml and puts respectively in 50 m1 measuring bottles, adds methyl alcohol and is diluted to scale, shakes up.Under above-mentioned chromatographic condition, respectively sample introduction 20 μ L, result shows that hydrocortisone butyrate concentration and peak area in 30-45mg/L concentration range have good linear relationship.Regression equation Y=4475.3X+422.45.r＝0.9993。
Sample determination: get the each 20 μ L sample introductions of reference substance solution and need testing solution, read peak area value, calculate content by external standard method.HCB-21 content assaying method is identical with hydrocortisone butyrate method.
The stability under wet environment that can determine commercially available sample, patented method sample by this experiment is poor compared with embodiment 1-6 sample, and in embodiment 1-6, No. 4-6 better.
drug permeability test
Test method: get after the healthy rat anesthesia execution of 3 monthly ages, eliminate belly wool with scissors, take off undamaged skin, remove subcutis, after cleaning, be individually fixed in the liberation port of Franz diffusion cell, in receiving chamber, add pH7.4 phosphoric acid buffer to make release medium, keep endodermis and solution close contact.Getting 0.1ml liquid is coated on skin, regulate water-bath that outer jacket layer homo(io)thermism is spent in (37 ± 1), stirring velocity is 100rpm, respectively at 0,0.15,0.5,0.75,1,1.5,2 hour absorption release medium 4ml, adds equivalent PBS liquid simultaneously.Discharge liquid and determine concentration C i by the method for Chinese Pharmacopoeia version in 2010, try to achieve drug per unit area accumulation transit dose Q:Q=CiV/A according to following formula.In formula, Q is drug per unit area accumulation transit dose, and Ci is the drug level in release medium in the t time, and V is reception chamber volume, and A is skin diffusion area.With Q and C, the time is carried out to linear regression respectively, try to achieve rate of permeation (J/ μ g.h
-1)
The preparation of reference examples medicine: change activeconstituents in the prescription of FORMULATION EXAMPLE 1-3 into commercially available hydrocortisone butyrate, changing activeconstituents in the prescription of FORMULATION EXAMPLE 4-6 the hydrocortisone butyrate of patented method into, all the other are constant, prepare corresponding reference examples 1-6.
Get the pharmaceutical composition that FORMULATION EXAMPLE 1-6 and reference examples 1-6 class value obtain, carry out body outer osmotic test experiment, the micro mist of the D90 particle size range 25-35 μ m of hydrocortisone butyrate semihydrate in all FORMULATION EXAMPLE, differ and be less than or equal to 1 μ m with D90, the D50 grain diameter value of hydrocortisone butyrate in corresponding control formulation embodiment, the D90 particle diameter of for example hydrocortisone butyrate semihydrate is 41 μ m, D50 particle diameter is 32 μ m, hydrocortisone butyrate D90 particle size range is between 40-42 μ m, D50 particle size range is at 32-33 μ m., can think in this experiment particle diameter on rate of permeation without impact.Result is as follows:
Test shows, adopts embodiment 1-6 hydrocortisone butyrate semihydrate as activeconstituents take the hydrocortisone butyrate of commercially available sample, patented method sample as the transdermal effect of activeconstituents in preparation is weaker than, and in embodiment 1-6, No. 4-6 better.
Claims (10)
1. a hydrocortisone butyrate semihydrate, structure is as follows
2. hydrocortisone butyrate semihydrate as claimed in claim 1, is characterized in that its X ray result is diffuse type, there is no sharp-pointed absorption peak.
3. hydrocortisone butyrate semihydrate as claimed in claim 1, is characterised in that its differential scanning calorimetric analysis result has endotherm(ic)peak at 185-210 ℃ and 95-120 ℃.
4. hydrocortisone butyrate semihydrate as claimed in claim 1, be characterised in that its preparation method is that hydrocortisone butyrate is dissolved in the mixing solutions of tetrahydrofuran (THF), ethanol, add the water of mixed liquor volume 7-13%, under-70 to-60 ℃ of conditions freezing 2 hours again, solution freezes as solid, system is vacuumized, to vacuum tightness 18Pa, heating is warming up to-40 ℃, constant temperature 3 hours gradually; Be warming up to-20 ℃, constant temperature 6 hours; Be warming up to-10 ℃, constant temperature 4 hours; Be warming up to 0 ℃, constant temperature 4 hours, rises to 20 ℃ naturally, constant temperature 5 hours, 50 ± 5 ℃ dry, within 1 hour, often digest compound weight differential to interval and be less than or equal to 0.5 milligram and get final product.
5. hydrocortisone butyrate semihydrate preparation method as claimed in claim 4, is characterized in that tetrahydrofuran (THF) accounts for tetrahydrofuran (THF), alcohol mixed solvent ratio is 0.2 ± 0.05.
6. hydrocortisone butyrate semihydrate preparation method as claimed in claim 4, is characterized in that adding passing into carbonic acid gas after the water of mixed liquor volume 15-25% and carrying out saturated.
7. a pharmaceutical composition, is characterized in that containing hydrocortisone butyrate semihydrate as claimed in claim 1 and the excipient substance of one or more.
8. directly act on a pharmaceutical composition for skin, it is characterized in that containing hydrocortisone butyrate semihydrate claimed in claim 1 and one or more excipient substances as activeconstituents.
9. directly act on a pharmaceutical composition for skin, it is characterized in that being formed by the hydrocortisone butyrate semihydrate claimed in claim 1 as activeconstituents and the excipient substance of one or more.
10. directly act on a pharmaceutical composition for skin, it is characterized in that by the hydrocortisone butyrate semihydrate claimed in claim 1 as activeconstituents, form as the water of solid, consistency modifiers, wetting Agent for Printing Inks, emulsifying agent, pH buffer reagent, sanitas and the surplus of the oil-phase component of pharmaceutical excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410086992.4A CN103880907A (en) | 2014-03-11 | 2014-03-11 | Hydrocortisone-17-butyrate semihydrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410086992.4A CN103880907A (en) | 2014-03-11 | 2014-03-11 | Hydrocortisone-17-butyrate semihydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103880907A true CN103880907A (en) | 2014-06-25 |
Family
ID=50950068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410086992.4A Pending CN103880907A (en) | 2014-03-11 | 2014-03-11 | Hydrocortisone-17-butyrate semihydrate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103880907A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880906A (en) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | Hydrocortisone-17-butyrate semihydrate |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101652380A (en) * | 2007-02-05 | 2010-02-17 | 尼科克斯公司 | Discharge nitric oxide production steroid |
| CN101812108A (en) * | 2009-11-26 | 2010-08-25 | 天津金耀集团有限公司 | Synthesis of hydrocortisone butyrate |
| US7981877B2 (en) * | 2003-01-23 | 2011-07-19 | Patel Pravin M | Stabilized steroid composition and method for its preparation |
| CN103880906A (en) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | Hydrocortisone-17-butyrate semihydrate |
-
2014
- 2014-03-11 CN CN201410086992.4A patent/CN103880907A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981877B2 (en) * | 2003-01-23 | 2011-07-19 | Patel Pravin M | Stabilized steroid composition and method for its preparation |
| CN101652380A (en) * | 2007-02-05 | 2010-02-17 | 尼科克斯公司 | Discharge nitric oxide production steroid |
| CN101812108A (en) * | 2009-11-26 | 2010-08-25 | 天津金耀集团有限公司 | Synthesis of hydrocortisone butyrate |
| CN103880906A (en) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | Hydrocortisone-17-butyrate semihydrate |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880906A (en) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | Hydrocortisone-17-butyrate semihydrate |
| CN103880906B (en) * | 2014-03-11 | 2015-10-07 | 天津金耀集团有限公司 | A kind of hydrocortisone butyrate semihydrate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105646484A (en) | Crystal form B and preparation method | |
| CN102258531B (en) | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof | |
| WO2015168963A1 (en) | Crystalline form of chlorogenic acid and preparation method therefor | |
| CN103880906B (en) | A kind of hydrocortisone butyrate semihydrate | |
| CN106727338A (en) | Fenofibrate solid dispersion and its preparation method and application | |
| CN104326970B (en) | Levamlodipine maleate compound and preparation method and containing its pharmaceutical preparation | |
| CN106798750B (en) | A kind of preparation method of compound omeprazole dry suspension | |
| CN103880907A (en) | Hydrocortisone-17-butyrate semihydrate | |
| CN108017601A (en) | A kind of method of refined ranitidine alkali | |
| CN105693793B (en) | A kind of Ribavirin compound and its pharmaceutical composition | |
| CN103224504A (en) | Injection sodium cefonicid compound, preparation method and pharmaceutical composition | |
| Singh et al. | Modulation of volumetric properties of d (+)-glucose in aqueous 3-hydroxypropylammonium acetate solutions | |
| CN103877119A (en) | Hydrocortisone butyrate semihydrate zinc oxide pharmaceutical composition | |
| CN101596200B (en) | Preparation of compound of cycloartenyl ferulate and purification process thereof | |
| CN207506783U (en) | A kind of compound omeprazole dry suspension wet method preparation facilities | |
| CN103724359B (en) | A kind of amorphous cefotetan acid and prepared the method for Cefotetan Disodium and containing the pharmaceutical composition of this Cefotetan Disodium by it | |
| CN103130821B (en) | A kind of cefuroxime lysine and preparation thereof | |
| CN105055337A (en) | Medicament namely fasudil hydrochloride composite granules for treating cerebral ischemia | |
| CN105267161B (en) | A kind of cobamamide lyophilized preparation for injection composition and preparation method thereof | |
| CN103265459B (en) | A kind of novel sodium houttuyfonate compound, its preparation method and pharmaceutical composition thereof | |
| CN106565783A (en) | Fosaprepitant-meglumine crystal compound, preparation method thereof, and pharmaceutical composition | |
| CN106432275A (en) | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection | |
| CN105085548A (en) | Pharmaceutical cefotiam composition for treating infectious diseases | |
| CN105693716A (en) | Crystal form A and preparing method | |
| CN104971050A (en) | Freeze-dried powder injection of tropisetron hydrochloride composition serving as vomit-stopping drug and preparation method of freeze-dried powder injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140625 |
|
| WD01 | Invention patent application deemed withdrawn after publication |